Skip to main content
. Author manuscript; available in PMC: 2012 Mar 27.
Published in final edited form as: J Immunol. 2010 May 7;184(11):6514–6521. doi: 10.4049/jimmunol.0900448

Table III.

MART-126-35 and tumor specific lysis by CTL generated with MART-126-35 peptide analogs

Percentage Specific Lysis from polyclonal CTL lines generated with the indicated peptide
MART-126-35A27L MART-126-35E26S MART-126-35L33M
Patient E/T T2a T2+M26b A375 Mel526 T2 T2+M26 A375 Mel526 T2 T2+M26 A375 Mel526
MelPt-B 50
25
12.5		 * 0c
0
2		 40
31
21		 6
4
8		 58
45
30		 2
2
4		 63
52
41		 13
12
9		 80
70
58
MelPt-C 50
25
12.5		 9
10
9		 73
52
42		 3
5
2		 35
30
25		 2
7
1		 87
66
54		 8
5
2		 41
32
25		 9
12
11		 91
84
76		 0
2
5		 58
52
45
MelPt-D 50
25
12.5		 0
2
5		 50
42
35		 10
10
9		 32
30
25		 3
8
1		 87
65
54		 8
7
6		 41
32
25		 14
11
8		 90
84
75		 2
4
6		 57
54
45
MelPt-F 50
25
12.5		 6
3
2		 92
81
73		 5
5
5		 65
50
43		 23
21
22		 70
72
65		 2
3
5		 44
42
38
Helthy1 50
25
12.5		 2
4
1		 52
42
31		 3
7
6		 58
42
35		 0
0
0		 34
26
18		 9
5
8		 28
15
10		 2
6
5		 57
49
38		 13
13
10		 65
57
44
*

Where values are not shown, polyclonal cell lines were not established for that condition.

a

T2 is a TAP-deficient cell line that expresses peptide-unbound HLA-A2 molecules unless pulsed extracellularly. Here T2, has been pulsed with NYESO-1157-165 unless indicated otherwise.

b

M26 is an abbreviation for the unmodified MART-126-35 peptide.

c

Numbers represent the percentage specific lysis obtained from each target. T375 is a HLA-A2 positive/MART-1 negative